Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial

Oral capecitabine (Xeloda®) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in patients suitable for combination therapy, but is not yet approved by the UK National Institute for H...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassidy, J, Douillard, J-Y, Twelves, C, McKendrick, J J, Scheithauer, W, Bustová, I, Johnston, P G, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T S, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K K, Cowell, W, Garrison, L P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361258/
https://www.ncbi.nlm.nih.gov/pubmed/16622438
http://dx.doi.org/10.1038/sj.bjc.6603059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361258/
https://www.ncbi.nlm.nih.gov/pubmed/16622438
http://dx.doi.org/10.1038/sj.bjc.6603059

Ejemplares similares